Dongwha Pharm.Co.Ltd (000020) - Total Liabilities

Latest as of March 2026: ₩238.27 Billion KRW ≈ $161.48 Million USD

Based on the latest financial reports, Dongwha Pharm.Co.Ltd (000020) has total liabilities worth ₩238.27 Billion KRW (≈ $161.48 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Dongwha Pharm.Co.Ltd - Total Liabilities Trend (2011–2025)

This chart illustrates how Dongwha Pharm.Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Dongwha Pharm.Co.Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.

Dongwha Pharm.Co.Ltd Competitors by Total Liabilities

The table below lists competitors of Dongwha Pharm.Co.Ltd ranked by their total liabilities.

Company Country Total Liabilities
Negri Sembilan Oil Palms Bhd
KLSE:2038
Malaysia RM223.87 Million
Immobile
WAR:GKI
Poland zł834.88 Million
Economic Investment Trust Ltd
TO:EVT
Canada CA$158.27 Million
Feng Ching Metal
TWO:2061
Taiwan NT$535.52 Million
Max India Limited
NSE:MAXIND
India Rs3.71 Billion
Tailim Packaging Co Ltd
KO:011280
Korea ₩376.99 Billion
CGRE AG
XETRA:CGX
Germany €25.33 Million
Eastland Equity Bhd
KLSE:2097
Malaysia RM254.27 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Dongwha Pharm.Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Dongwha Pharm.Co.Ltd market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.16 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.61 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.37 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Dongwha Pharm.Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Dongwha Pharm.Co.Ltd (2011–2025)

The table below shows the annual total liabilities of Dongwha Pharm.Co.Ltd from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 ₩240.73 Billion
≈ $163.14 Million
+10.45%
2024-12-31 ₩217.96 Billion
≈ $147.71 Million
+38.02%
2023-12-31 ₩157.92 Billion
≈ $107.02 Million
+91.50%
2022-12-31 ₩82.46 Billion
≈ $55.88 Million
-5.94%
2021-12-31 ₩87.67 Billion
≈ $59.41 Million
-3.79%
2020-12-31 ₩91.13 Billion
≈ $61.75 Million
+21.25%
2019-12-31 ₩75.15 Billion
≈ $50.93 Million
+2.67%
2018-12-31 ₩73.20 Billion
≈ $49.61 Million
+4.15%
2017-12-31 ₩70.28 Billion
≈ $47.63 Million
-1.95%
2016-12-31 ₩71.68 Billion
≈ $48.58 Million
-17.68%
2015-12-31 ₩87.07 Billion
≈ $59.01 Million
+4.47%
2014-12-31 ₩83.35 Billion
≈ $56.48 Million
-6.28%
2013-12-31 ₩88.93 Billion
≈ $60.27 Million
-8.59%
2012-12-31 ₩97.29 Billion
≈ $65.93 Million
-11.40%
2011-12-31 ₩109.81 Billion
≈ $74.42 Million
--

About Dongwha Pharm.Co.Ltd

KO:000020 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$95.42 Million
₩140.81 Billion KRW
Market Cap Rank
#19425 Global
#960 in Korea
Share Price
₩5080.00
Change (1 day)
-2.12%
52-Week Range
₩5080.00 - ₩7060.00
All Time High
₩28554.43
About

Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, d… Read more